パーキンソン病・パーキンソン症候群の在宅ケア

出版社： 中央法規出版
著者：
発行日： 2016-05-30
分野： 看護学  >  臨床/成人/老人
ISBN： 9784805853689
電子書籍版： 2016-05-30
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

3,960 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

3,960 円(税込)

購入する

商品紹介

基本知識から最新情報までを、わかりやすく解説！訪問看護師や在宅医、リハ職、ケアマネジャー、介護職など在宅ケアの関係職に向け、パーキンソン病・パーキンソン症候群に関する基本知識から最新情報までをわかりやすく解説する。ケアにあたり必要な知識と技術、合併症への対応や家族支援の方法などを事例も交えて紹介する。

目次

  • パーキンソン病・パーキンソン症候群の在宅ケア

    ―目次―

    第１章　パーキンソン病・パーキンソン症候群の医学知識
    　1.パーキンソン病、レビー小体病
    　2.パーキンソン症候群
    　3.進行性核上性麻痺−多彩な症状と経過
    　ほか

    第２章　合併症とケア−在宅でのポイント
    　1.パーキンソン症状のみかたと合併症
    　2.転倒（歩行障害）
    　3.嚥下障害
    　ほか

    第３章　パーキンソン病・パーキンソン症候群の薬の使い方と副作用
    　1.パーキンソン病の薬
    　2.パーキンソン病の外科治療

    第４章　リハビリテーションと在宅環境
    　1.初期・中期のリハビリテーション、在宅での危険サインの
    　　　みかたと対応
    　2.すくみ足、転倒の対策
    　3.パーキンソン症候群の在宅環境

    第５章　在宅におけるアプローチの実際
    　1.うつ症状が前景に出たレビー小体病の訪問看護
    　2.無動・無言状態が改善した進行性核上性麻痺の訪問看護
    　3.療養困難な在宅患者への挑戦
    　ほか

    第６章　在宅で安心して暮らすための諸制度
    　1.地域で安心して暮らすための制度・社会資源の活用
    　2.地域医療ネットワークの取り組みと課題
    　3.地域包括支援センターの役割
    　4.パーキンソニズム・認知症の地域医療相談会：実績と課題

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 パーキンソン病・パーキンソン症候群の医学知識

P.17 掲載の参考文献
1) Kosaka K, Oyanagi S, Matsushita M, et al. Presenile dementia with Alzheimer-, Pick- and Lewy body changes. Acta Neuropathol 1976 ; 36 : 221-233.
PubMed
2) Pringsheim T, Jette N, Frolkis A, et al. The Prevalence of Parkinson's Disease : A Systematic Review and Meta-analysis. Mov Disord 2014 ; 29 : 1583-1590.
PubMed
3) 平山恵造. 神経症候学. 文光堂 ; 1971. p.587.
 
4) Aarsland D, Bronnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia : frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007 ; 78 (1) : 36-42.
PubMed
5) Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene : Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008 ; 63 (2) : 184-192.
PubMed
6) Kitada T, Asakawa S, Hattori N, et al. Mutations in the Parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998 ; 392 : 605-608.
 
7) Cilia R, Cereda E, Klersy C, et al. Parkinson's disease beyond 20 years. J Neurol Neurosurg Psychiatry 2015 ; 86 : 849-855.
PubMed
P.29 掲載の参考文献
1) Web サイト 難病情報センター 厚生労働省. 進行性核上性麻痺. 2012 Apr 2 Available from http://www.nanbyou.or.jp/entry/276 Japanese.
 
2) Webサイト 難病情報センター 厚生労働省. 大脳皮質基底核変性症. 2013 Sep 9 Available from http://www.nanbyou.or.jp/entry/291 Japanese.
 
3) Webサイト 難病情報センター 厚生労働省. 多系統萎縮症. 2011 Sep 27 Available from http://www.nanbyou.or.jp/entry/59 Japanese.
 
4) 日本正常圧水頭症学会特発性正常圧水頭症診療ガイドライン作成委員会編. 特発性正常圧水頭症診療ガイドライン. メジカルビュー社 ; 2011.
 
5) Olanow CW, Schapira AHV. Parkinson's disease and other movement disorders. In : Harriosn's Principles of Onternal medicine, 18th Ed. ed by Longo, et al. NY, Mc Grew Hill, 2012, p.3317-3335.
 
6) Gash DM, Rutland K, Hudson NL, et al. Trichloroethylene : Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann Neurol 2008 ; 184-192.
PubMed
7) Sieh W, Choi Y, Chapman NH, et al. Identification of novel susceptibility loci for Guam neurodegenerative disease : challenges of genome scans in genetic isolates. Hum Mol Genet 2009 ; 1 ; 18 (19) : 3725-3738.
 
8) Caparros-Lefebvre D, Sergeant N, Lees A, et al. Guadeloupean parkinsonism : a cluster of progressive supranuclear palsy-like tauopathy. Brain 2002 ; 125 (Pt 4) : 801-811.
 
P.41 掲載の参考文献
1) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 : 1-9.
 
2) Williams DR, Lees AJ. Progressive supranuclear palsy : clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009 ; 8 : 270-279.
PubMed
3) Zampieri C, Di Fabio RP. Balance and eye movement training to improve gait in people with progressive supranuclear palsy : quasi-randomized clinical trial. Phys Ther 2008 ; 88 : 1460-1473.
PubMed
P.48 掲載の参考文献
1) Graham JG, Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 1969 ; 32 : 28-34.
 
2) Papp MI, Kahn JE, Lanton PL. Glial sytoplasmic inclusions in the CNS of patients with multiple system atrophy ( striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neuro Sci 1989 ; 94 : 79-100.
 
3) Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008 ; 71 : 670-676.
 
4) Mitsui J, Matsukawa T, Ishiura H, et al. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med 2013 ; 369 : 233-244.
PubMed
5) Jellinger K. Neuropathology of Multiple System Atrophy : New Thoughts About Pathogenesis. Mov Disord 2014 ; 29 : 1720-1741.
PubMed
6) Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple system atrophy. An analysis of 230 Japanese patients. Brain 2002 ; 125 : 1070-1083.
PubMed
7) Wenning GK, Geser F, Krismer F, et al. The natural history of multiple system atrophy : a prospective European cohort study. Lancet Neurol 2013 ; 12 : 264-274.
PubMed
P.58 掲載の参考文献
1) Alzheimer A. Uber einen eigenartigen schweren Erkrankungsprozes der Hirnrinde. Neurol Central 1906 ; 25 : 1134.
 
2) Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacological Sci 1991 ; 12 : 383-388.
 
3) Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016 ; 79 : 110-119.
PubMed
4) McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's dement 2011 ; 7 : 263-269.
 
5) Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease : recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011 ; 7 : 270-279.
 
6) Iwasaki K, Satoh-Nakagawa T, Maruyama M, et al. A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry 2005 ; 66 : 248-252.
PubMed
7) 小阪憲司, 松下正明, 小柳新策ら. Lewy小体病の臨床病理学的研究. 精神神経学雑誌 1980 ; 82 : 292-311.
 
8) McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 2005 ; 65 : 1863-1872.
PubMed
9) Iwasaki K, Maruyama M, Tomita N, et al. Effects of the traditional Chinese herbal medicine Yi-Gan San for cholinesterase inhibitor-resistant visual hallucinations and neuropsychiatric symptoms in patients with dementia with Lewy bodies. J Clin Psychiatry 2005 ; 66 : 1612-1613.
PubMed
10) Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 1996 ; 47 : 1-9.
 
11) Litvan I, Phipps M, Pharr VL, et al. Randomized Placebo-controlled trial of donepezil in patients with progressive sapranuclear palsy. Neurology 2001 ; 57 : 467-473.
PubMed
12) Newman GC. Treatment of progressive supranuclear palsy with tricyclic antidepressants. Neurology 1985 ; 35 : 1189-1193.
PubMed
13) 藤野泰祐, 中島雅士, 坪井義夫ら. 進行性核上性麻痺 (PSP) に対するTandospirone citrate (5-HT1A agonist) の効果. 臨床神経 2002 ; 42 : 42-44.
 
14) Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003 ; 54 Suppl 5 : S15-19.
 
15) Shelley BP, Hodges JR, Kipps CM, et al. Is the pathology of corticobasal syndrome predictable in life? Mov Disord 2009 ; 24 : 1593-1599.
PubMed
P.66 掲載の参考文献
1) Bang J, Spina S, Miller BL. Frontotemporal dementia. The Lancet 2015 ; 386:1672-1682.
 
2) Chare L, Hodges JR, Leyton CE, et al. New criteria for frontotemporal dementia syndromes : clinical and pathological diagnostic implications. J Neurol Neurosurg Psychiatry 2014 ; 85 : 865-870.
PubMed
3) https://bsd.neuroinf.jp/wiki/
 
4) WHO. http://www.who.int/mediacentre/factsheets/fs362/en/
 
5) Wu YT, Fratiglioni L, Matthews FE, et al. Dementia in western Europe : epidemiological evidence and implications for policy making. Lancet Neurol 2015.
PubMed
6) 兵頭隆幸, 池田学, 田邊敬貴. アルツハイマー病とほかの変性性痴呆性疾患の鑑別, よくわかるアルツハイマー病. 中野今治, 水澤英洋編, 永井書店 ; 2004. p.106-120.
 
7) Seely WW, Miller BL. Dementia in Harrison's Principles of Internal Medicine, In : Longo DL, Fauci AS, Kasper DL, et al. editors. NY : McGraw Hill ; 2012. p.3300-3316.
 
8) Chew J, Gendron TF, Prudencio M, et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 2015 ; 348 : 1151-1154.
PubMed
P.87 掲載の参考文献
1) 織茂智之. レビー小体型認知症と自律神経障害 (総論). 木ノ下徹 (編), 認知症医療. 中山書店 ; 2014. p.38-44.
 
2) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 ; 24 : 197-211.
PubMed
3) Verbaan D, Marinus J, Visser M, et al. Patient-reported autonomic symptoms in Parkinson disease. Neurology 2007 ; 69 : 333-341.
PubMed
4) Kaufmann H, Goldstein DS. Autonomic dysfunction in Parkinson's disease. In : Buijs RM, Swaab DF, editors. Handb Clin Neurol 3rd ed. Amsterdam : Elsevier ; 2013. p.259-278.
 
5) Benarroch EE. The arterial baroreflex : functional organization and involvement in neurologic disease. Neurology 2008 ; 71 : 1733-1738.
PubMed
6) 長谷川康博, 古池保雄. 知っていますか? 食事性低血圧. 南山堂 ; 2004.
 
7) 織茂智之. 認知症と血圧変動. 木ノ下徹 (編), 認知症医療. 中山書店 ; 2014. p.71-75.
 
8) Sakakibara R, Uchiyama T, Yamanishi T, et al. The voiding genitourinary dysfunction in Parkinson's disease. Mov Disord 2010 ; 1 : 2-12.
 
9) Schestatsky P, Valls-Sole J, Ehlers JA, et al. Hyperhidrosis in Parkinson's disease. Mov Disord 2006 ; 21 : 1744-1748.
PubMed
10) Stiasny-Kolster K, Mayer G, Schafer S, et al. The REM sleep behavior disorder screening questionnaire : a new diagnostic instrument. Mov Disord 2007 ; 22 : 2386-2393.
PubMed
11) Miyamoto T, Miyamoto M, Iwanami M, et al. The REM sleep behavior disorder screening questionnaire : validation study of Japanese version. Sleep Med 2009 ; 10 : 1151-1154.
PubMed
12) Nihei Y, Takahashi K, Koto A, et al. REM sleep behavior disorder in Japanese patients with Parkinson's disease : a multicenter study using the REM sleep behavior disorder screening questionnaire. J Neurol 2012 ; 259 : 1606-1612.
PubMed
13) Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson's disease : a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011 ; 26 : 90-99.
PubMed
14) Johns MW. A new method for measuring daytime sleepiness : the Epworth sleepiness scale. Sleep 1991 ; 14 : 540-545.
PubMed
15) 福原俊一, 竹上未紗, 鈴鴨よしみら. 日本語版the Epworth Sleepiness Scale (JESS). 日呼吸会誌 2006 ; 44 : 896-898.
Medical*Online
16) Yeung EYH, Cavanna AE. Sleep attacks in patients with Parkinson's disease on dopaminergic medications : a systematic review. Movmnt Disords Clncl Practice 2014 ; 1 : 307-316. doi : 10.1002/mdc3. 12063.
 
17) 日本神経治療学会治療指針作成委員会編. 標準的神経治療 : Restless legs症候群. 神経治療 2012 ; 29 : 73-109.
 
18) Ekbom K. Restless legs syndrome : a clinical study. Acta Med Scand Suppl 1945 ; 158 : 1-123.
 
19) Allen R, Picchietti D, Hening W, et al. Restless legs syndrome : diagnostic criteria, special considerations, and epidemiology. Sleep Med 2003 ; 4 : 101-119.
PubMed
20) Clemens S, Hochman S : Conversion of the modulatory actions of dopamine on spinal reflexes from depression to facilitation in D3 receptor knockout mice. J Neurosci 2004 : 24 : 11337-11345.
PubMed
21) Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000 : 54 : 1698-1700.
PubMed
22) Allen RP, Barker PB, Wehri F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001 : 56 : 263-265.
 
23) Winkelmann J, Wetter TC, Collado-Seidel V, et al. Clinical characteristics and frequency of the hereditary restless legs syndrome in a population of 300 patients. Sleep 2000 : 23 : 597-602.
 
24) Pichler I, Hicks AA, Pramstaller PP. Restless legs syndrome : an update on genetics and future perspectives. Clin Genet 2008 : 73 : 297-305.
PubMed
25) Wayne AH, Richard PA, Arthur SW, et al. Motor Functions and dysfunctions of sleep. Sleep Disorders Medicine (Sud-hansu Chokroverty), Philadelphia, 2009 : 397-435.
 
26) Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomno-graphic, and genetic characteristics of restless legs syndrome : a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997 : 12 : 61-65.
 
27) Inoue Y, Hirata K, Kuroda K, et al. Efficacy and safety of pramipexole in Japanese patients with primary restless legs syndrome : a polysomnographic randomized, double-blind, placebo-controlled study. Sleep Med 2010 : 11 : 11-16.
PubMed
28) Inoue Y, Shimizu T, Hirata K, et al. Efficacy and safety of rotigotine in Japanese patients with restless legs syndrome : a phase 3, multicenter, randomized, placebo-controlled, double-blind, parallel-group study. Sleep Med 2013 : 14 : 1085-1091.
 
29) Inoue Y, Uchimura N, Kuroda K, et al. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry 2012 ; 36 : 251-257.
PubMed
P.98 掲載の参考文献
1) Matsuda H, Mizumura S, Nemoto K, et al. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer Disease. AJNR Am J Neuroradiol 2012 ; 33 : 1109-1114.
 
2) Shigemoto Y, Matsuda H, Kamiya K, et al. In vivo evaluation of gray and white matter volume loss in the parkinsonian variant of multiple system atrophy using SPM8 plus DARTEL for VBM. Neuroimage Clin 2013 ; 2 : 491-496.
PubMed
3) Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns of atrophy that help differentiate progressive supranuclear palsy and Parkinson's disease. Neuroimage 2004 ; 23 : 663-669.
PubMed
4) Josephs KA, Whitwell JL, Dickson DW, et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008 ; 29 : 280-289.
PubMed
5) Borghammer P, Chakravarty M, Jonsdottir KY, et al. Cortical hypometabolism and hypoperfusion in Parkinson's disease is extensive : probably even at early disease stages. Brain Struct Funct 2010 ; 214 : 303-317.
PubMed
6) Imon Y, Matsuda H, Ogawa M, et al. SPECT image analysis using statistical parametric mapping in patients with Parkinson's disease. J Nucl Med 1999 ; 40 : 1583-1589.
PubMed
7) Sakurai K, Imabayashi E, Ito K, et al. The utility of cerebral perfusion SPECT analysis using SPM8, eZIS and vbSEE for the diagnosis of multiple system atrophy-parkinsonism. Ann Nucl Med 2015 ; 29 : 206-213.
 
8) Minoshima S, Foster NL, Sima AA, et al. Alzheimer's disease versus dementia with Lewy bodies : cerebral metabolic distinction with autopsy confirmation. Ann Neurol 2001 ; 50 : 358-365.
PubMed
9) Mori T, Ikeda M, Fukuhara R, et al. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology 2006 ; 66 : 935-937.
PubMed
10) Gunther I, Hall H, Halldin C, et al. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization : autoradiographic evaluation in the human brain. Nucl Med Biol 1997 ; 24 : 629-634.
PubMed
11) Tossici-Bolt L, Hoffmann SM, Kemp PM, et al. Quantification of [123I] FPCIT SPECT brain images : an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 2006 ; 33 : 1491-1499.
PubMed
12) Calvini P, Rodriguez G, Inguglia F, et al. The basal ganglia matching tools package for striatal uptake semi-quantification : description and validation. Eur J Nucl Med Mol Imaging 2007 ; 34 : 1240-1253.
PubMed
13) Roselli F, Pisciotta NM, Pennelli M, et al. Midbrain SERT in degenerative parkinsonisms : a 123I-FP-CIT SPECT study. Mov Disord 2010 ; 25 : 1853-1859.
PubMed
14) Booij J, de Jong J, de Bruin K, et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine : a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med 2007 : 48 : 359-366.
PubMed
15) Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias : a systematic review and a metaanalysis. J Neuroimaging 2012 ; 22 : 111-117.
 
16) Miyamoto T, Orimo S, Miyamoto M, et al. Follow-up PET studies in case of idiopathic REM sleep behavior disorder. Sleep Med 2010 ; 11 : 100-101.
PubMed
17) Treglia G, Cason E, Cortelli P, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases : complementary or alternative techniques? J Neuroimaging 2014 ; 24 : 149-154.
PubMed
18) Adachi T, Kitayama M, Wada-Isoe K, et al. Autopsy-confirmed progressive supranuclear palsy with decreased uptake of metaiodobenzylguanidine. Clin Neurol Neurosurg 2013 ; 115 : 1555-1557.
PubMed
P.107 掲載の参考文献
1) Goedert M. Alzheimer's and Parkinson's diseases : The prion concept in relation to assembled Aβ, tau, and α-synuclein. Science 2015 ; 349 : 1-9.
 
2) Dickson DW. Neuropathology of non-Alzheimer degenerative disorders. Alzheimers Res Ther 2014 ; 3 : 1-23.
 
3) Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet 2015 ; 24 ; 1672-1682.
 
4) Wang Y, Mandelkow E. Tau in physiology and pathology. Nat Rev Neurosci 2016 ; 17 : 22-35.
 
5) Asai H, Ikezu S, Tsunoda S, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci 2015 ; 18 : 1584-1593.
PubMed
6) Watts JC, Condello C, Stohr J, et al. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci U S A 2014 ; 111 : 10323-10328.
 
7) Boluda S, Iba M, Zhang B, et al. Differential induction and spread of tau pathology in young PS19 tau transgenic mice following intracerebral injections of pathological tau from Alzheimer's disease or corticobasal degeneration brains. Acta Neuropathol 2015 ; 129 : 221-237.
PubMed
8) Arai T, Ikeda K, Akiyama H, et al. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol 2004 ; 55 : 72-79.
PubMed
9) Taniguchi-Watanabe S, Arai T, Kametani F, et al. Biochemical classification of tauopathies by immunoblot, protein sequence and mass spectrometric analyses of sarkosyl-insoluble and trypsin-resistant tau. Acta Neuropathol 2015 on line ; Nov 4.
 
10) Prusiner SB, Woerman AL, Mordes DA,et al. Evidence for α-synuclein prions causing multiple system atrophy in humans with parkinsonism. Proc Natl Acad Sci U S A 2015 22 ; 112 : E5308-5317.
 
P.115 掲載の参考文献
1) Barker RA, Barrett J, Mason SL, et al. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 2013 ; 12 (1) : 84-91.
PubMed
2) Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001 ; 344 (10) : 710-719.
PubMed
3) Olanow CW, Goetz CG, Kordower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease.Ann Neurol 2003 ; 54 (3) : 403-414.
PubMed
4) http://www.transeuro.org.uk
 
5) Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease : a dose escalation, open-label, phase 1/2 trial. Lancet 2014 ; 383 (9923) : 1138-1146.
PubMed

第2章 合併症とケア - 在宅でのポイント

P.131 掲載の参考文献
1) 平山恵造. 神経症候学. 文光堂 ; 1971. p.587.
 
P.138 掲載の参考文献
1) Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease : a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology 1990 ; 40 : 1529-1534.
 
2) Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease : The inevitability of dementia at 20 years. Mov Disord 2008 ; 23 : 837-844.
PubMed
3) Bloem BR, van Vugt JP, Beckley DJ. Postural instability and falls in Parkinson's disease. Adv Neurol 2001 ; 87 : 209-223.
PubMed
4) Okuma Y. Practical approach to freezing of gait in Parkinson's disease. Pract Neurol 2014 ; 14 : 222-230.
PubMed
5) Bloem BR, Munneke M, Carpenter MG. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 2003 ; 61 : 1023-1024.
PubMed
6) Ashburn A, Stack E, Ballinger C, et al. The circumstances of falls among people with Parkinson's disease and the use of falls diaries to facilitate reporting. Disabil Rehabil 2008 ; 30 : 1205-1212.
PubMed
7) Stack E, Ashburn A, Jupp K. Postural instability during reaching tasks in Parkinson's disease. Physiother Res Int 2005 ; 10 : 146-153.
PubMed
P.154 掲載の参考文献
1) Yamamoto T, Kobayashi Y, Murata M. Risk of pneumonia onset and discontinuation of oral intake following videofluorography in patients with Lewy body disease. Parkinsonism Relat Disord 2010 ; 16 (8) : 503-506.
PubMed
2) 山本敏之, 村田美穂. こうしよう! パーキンソン症候群の摂食嚥下障害. アルタ出版 ; 2014.
 
3) Yamamoto T, Ikeda K, Usui H, et al. Validation of the Japanese translation of the Swallowing Disturbance Questionnaire in Parkinson's disease patients. Qual Life Res 2012 Sep ; 21 (7) : 1299-303.
PubMed
4) Muller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Archives of neurology 2001 ; 58 (2) : 259-264.
PubMed
5) Pehlivan M, Yuceyar N, Ertekin C, et al. An electronic device measuring the frequency of spontaneous swallowing : digital phagometer. Dysphagia 1996 ; 11 (4) : 259-264.
PubMed
6) 植田耕一郎, 岡田澄子, 北住映二ら. 摂食・嚥下障害の評価 (簡易版) 日本摂食嚥下リハビリテーション学会医療検討委員会案. 日摂食嚥下リハ会誌 2011 ; 15 (1) : 96-101.
 
7) Correa-Flores M, Arch-Tirado E, Villeda-Miranda A, et al. Analysis of oropharyngeal dysphagia through fibroendoscopy evaluation of swallowing in patients with Parkinson's disease. Cir Cir 2012 ; 80 (1) : 31-37.
PubMed
8) Logemann JA, Gensler G, Robbins J, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008 ; 51 (1) : 173-183.
PubMed
9) Nakano K, Hokamura K, Taniguchi N, et al. The collagen-binding protein of Streptococcus mutans is involved in haemorrhagic stroke. Nat Commun 2011 ; 27 : 2 : 485.
 
10) Yoshino A, Ebihara T, Ebihara S, et al. Daily oral care and risk factors for pneumonia among elderly nursing home patients. JAMA 2001 ; 286 (18) : 2235-2236.
PubMed
11) クローズアップ現代長寿の鍵は "口" にあり～口腔ケア最前線～. NHK総合 2014年12月1日 (月) 放送. Available from http://www.nhk.or.jp/gendai/kiroku/detail02_3587_all.html.Japnanese.
 
12) 聖隷三方原病院嚥下チーム. 嚥下障害ポケットマニュアル 第2版. 医歯薬出版 ; 2003.
 
13) 要介護者の口腔ケア-国立長寿医療研究センター- http://www.ncgg.go.jp/hospital/iryokankei/documents/oralcavitycare.pdf
 
14) 角保徳, 植松宏. 5分でできる口腔ケア 介護のための普及型口腔ケアシステム. 医歯薬出版 ; 2004.
 
15) 「情報ネットワークを活用した行政・歯科医療機関・病院等の連携による要介護者口腔保健医療システムの開発に関する研究班」. 口腔ケアマニュアル. 2004.
 
16) 入院患者に対するオーラルマネジメント. 財団法人8020推進財団 ; 2008.
 
17) 日本口腔ケア学会学術委員会 : 口腔ケアガイド. 文光堂 ; 2012.
 
18) 長野赤十字病院口腔ケアチームOCTマニュアル第一版. 2013.
 
P.169 掲載の参考文献
1) パーキンソン病治療ガイドライン作成委員会. パーキンソン病治療ガイドライン 2011. 医学書院 ; 2011. p.126-129.
 
2) 日本呼吸器学会 呼吸器感染症に関するガイドライン作成委員会. 医療・介護関連肺炎診療ガイドライン. 日本呼吸器学会 ; 2011.
 
3) 宮森正ら. 在宅介護スコア. 日本プライマリ・ケア学会誌 1992 ; 15 (4) : 58-64.
 
4) 織茂智之. レビー小体型認知症と自律神経障害 (総論). 木ノ下徹編. 認知症医療. 中山書店 ; 2014. p.38-44.
 
5) Palma JA, Carmona-Abellan MM, Barriobero N, et al. Is cardiac function impaired in premotor Parkinson's disease? A retrospective cohort study. Mov Disord 2013 ; 28 : 591-596.
PubMed
6) 堀田知光. 貧血 総論. 杉本恒明ら編. 内科学. 朝倉書店 ; 2008. p.1789-1793.
 
7) Wakabayashi K, Takahashi H, Takeda S, et al. Parkinson's disease : the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 1988 ; 76 : 217-221.
 
8) Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003 ; 24 : 197-211.
PubMed
9) Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015 ; 30 : 350-358.
PubMed
10) Holmqvist S, Chutna O, Bousset L. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014 ; 128 : 805-820.
 
11) Erny D, Hrabe de Angelis AL, Jaitin D, et al. Host microbiota constantly control maturation and function of microglia in the CNS. Nat Neurosci 2015 ; 18 : 965-977.
PubMed
12) 土井啓員, 榊原隆次, 岸雅彦ら. パーキンソン病と消化管機能障害. 臨床神経 2013 ; 33 : 1382-1384.
 
P.172 掲載の参考文献
1) 半田俊之介. 浮腫. 杉本恒明, 小俣敏男, 水野美邦編, 内科学. 朝倉書店 ; 2003 : 156-159.
 
2) 神出計ら. 高齢者の浮腫. 日内誌 2015 ; 104 : 330-334.
 
P.179 掲載の参考文献
1) 榊原隆次, 岸 雅彦. パーキンソン病の自律神経障害. 東邦医会誌 2009 ; 56 : 296-305.
Medical*Online
P.187 掲載の参考文献
1) Langston JW. The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 2006 ; 59 : 591-596.
 
2) Coelho M, Ferreira JJ. Late-stage Parkinson disease. Nat Rev Neurol 2012 ; 8 : 435-442.
 
3) Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 2008 ; 23 : 183-189.
PubMed
4) Aarsland D, Pahlhagen S, Ballard CG, et al. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol 2011 ; 8 : 35-47.
PubMed
5) Costa FH, Rosso AL, Maultasch H, et al. Depression in Parkinson's disease : diagnosis and treatment. Arq Neuropsiquiatr 2012 ; 70 : 617-620.
PubMed
6) Veazey C, Aki SO, Cook KF, et al. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005 ; 17 : 310-323.
PubMed
7) Schuurman AG, van den Akker M, Ensinck KT, et al. Increased risk of Parkinson's disease after depression : a retrospective cohort study. Neurology 2002 ; 58 : 1501-1504.
PubMed
8) Gustafsson H, Nordstrom A, Nordstrom P. Depression and subsequent risk of Parkinson disease : A nationwide cohort study. Neurology 2015 ; 84 : 2422-2429.
PubMed
9) Bomasang-Layno E, Fadlon I, Murray AN, et al. Antidepressive treatments for Parkinson's disease : A systematic review and meta-analysis. Parkinsonism Relat Disord. in Press.
 
10) Rios Romenets S, Anang J, Fereshtehnejad SM, et al. Tango for treatment of motor and non-motor manifestations in Parkinson's disease : a randomized control study. Complement Ther Med 2015 ; 23 : 175-184.
PubMed
11) Pagonabarraga J, Kulisevsky J, Strafella AP, et al. Apathy in Parkinson's disease : clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015 ; 14 : 518-531.
PubMed
12) Aarsland D, Marsh L, Schrag A. Neuropsychiatric symptoms in Parkinson's disease. mov disorder 2009 ; 24 : 2175-2186.
PubMed
13) Kirsch-Darrow L, Fernandez HH, Marsiske M, et al. Dissociating apathy and depression in Parkinson disease. Neurology 2006 ; 67 : 33-38.
PubMed
14) 葛西真理, 目黒謙一, 中村馨. Apathy Evaluation Scale介護者評価の日本語版 (AES-I-J) 作成. 日本老年医学会雑誌 2014 ; 51 : 445-452.
 
15) Starkstein SE, Brockman S, Hayhow BD. Psychiatric syndromes in Parkinson's disease. Curr Opin Psychiatry 2012 ; 25 : 468-472.
PubMed
16) Pedersen KF, Alves G, Larsen JP, et al. Psychometric properties of the Starkstein Apathy Scale in patients with early untreated Parkinson disease. Am J Geriatr Psychiatry 2012 ; 20 : 142-148.
PubMed
17) 岡田和悟, 小林祥泰, 青木耕ら. やる気スコアを用いた脳卒中後の意欲低下の評価. 脳卒中 1998 ; 20 : 318-323.
Medical*Online
18) Santangelo G, Vitale C, Trojano L, et al. Relationship between apathy and cognitive dysfunctions in de novo untreated Parkinson's disease : a prospective longitudinal study. Eur J Neurol 2015 ; 22 : 253-260.
PubMed
19) Loas G, Krystkowiak P, Godefroy O, et al. Anhedonia in Parkinson's disease : an overview. J Neuropsychiatry Clin Neurosci 2012 ; 24 : 444-451.
PubMed
20) Nagayama H, Kubo S, Hatano T, et al. Validity and reliability assessment of a Japanese version of the Snaith-Hamilton pleasure scale. Intern Med 2012 ; 51 : 865-869.
PubMed
21) Dissanayaka NN, Sellbach A, Matheson S, et al. Anxiety disorders in Parkinson's disease : prevalence and risk factors. Mov Disord 2010 ; 25 : 838-845.
PubMed
22) Bolluk B, Ozel-Kizil ET, Akbostanci MC, et al. Social anxiety in patients with Parkinson's disease. J Neuropasychiatry Clin Neurosci 2010 ; 22 : 390-394.
PubMed
23) Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson's disease : a large Australian retrospective study. J Neurol Neurosurg Psychiatry 2014 ; 86 : 324-330.
PubMed
24) Stowe RL, Ives NJ, Clarke C, et al. Dopamine agonist therapy in early Parkinson's disease. Cochran Database Syst Rev 2008 ; 16 : CD0006564.
 
25) Friedman JH. Parkinson disease psychosis : Update. Behav Neurol 2013 ; 27 : 469-477.
PubMed
P.195 掲載の参考文献
1) Dehydration and Parkinson's Disease Houston Parkinson's Disease Research, Education and Clinical Center 6 (2) 2007. http://www.parkinsons.va.gov/Houston/documents/Pathways_07Fall.pdf (2015. 5. 2アクセス)
 
2) Steven McGee. 柴田寿彦訳, マクギーの身体診断学, 第2版. 診断と治療社.
 
3) Varanese S, Birnbaum Z, Rossi R, et al. Treatment of Advanced Parkinson's Disease. Parkinsons Dis 2010 ; 2010 : 480260. Published online 2011 Feb 7.
 

第3章 パーキンソン病・パーキンソン症候群の薬の使い方と副作用

P.209 掲載の参考文献
1) パーキンソン病治療ガイドライン作成委員会編. パーキンソン病治療ガイドライン 2011. http://www.neurology-jp.org/guidelinem/parkinson.html
 
2) Poewe W, Antonini A, Zijimans JC, et al. Levodopa in the treatment of Parkinson's disease : an old drug still going strong. Clin Interv Ageing 2010 ; 5 : 229-238.
 
3) 小坂憲司編著. レビー小体型認知症の診断と治療. Harunosora ; 2014.
 
P.215 掲載の参考文献
1) Ngoga D, Mitchell R, Kausar J, et al. Deep brain stimulation improves survival in severe Parkinson's disease. J Neurol Neurosurg Psychiatry 2014 ; 85 (1) : 17-22.
PubMed

第4章 リハビリテーションと在宅環境

P.233 掲載の参考文献
1) アメステップ(R) 資料 http://www.nihon-eido.jp/amestep/
 
2) アメステップ(R) 動画 https://www.youtube.com/watch?v=4-3ckYKqJ_0
 
P.237 掲載の参考文献
1) http:www.idea-gr.co.jp
 

第5章 在宅におけるアプローチの実際

P.256 掲載の参考文献
1) 川島孝一郎. 重症高齢者等を支える在宅療養支援診療所等の量的・質的整備計画事業. 老人保健事業推進費等補助金 (老人保健健康増進等事業分), 平成19年度研究報告書. 2008. p.186, 211.
 
2) 川島孝一郎. 終末期の生活者の生き方を支える相談・支援マニュアル策定に関する研究. 厚生労働科学研究費補助金 厚生労働科学特別研究事業, 平成21年度研究報告書. 2010. p.75-76.
 
3) 千葉宏毅. 在宅末期がん患者と主介護者に対する熟達した在宅医師の初診時の説明内容に関する定性的研究. 日在医会誌 2014 ; 16 (1) : 21-26.
 
4) 川島孝一郎. おだやかに最期の日まで暮らすために 生きることの集大成を叶える在宅医療パンフレット. 仙台往診クリニック ; 2013. http://www.oushin-sendai.jp/
 
5) 川島孝一郎ら. 在宅だからICF. 訪問看護と介護 2014 ; 19 (2) : 101-145.
 
6) 川島孝一郎. 終末期の生活者の生き方を支える相談・支援マニュアル策定に関する研究. 厚生労働科学研究費補助金 厚生労働科学特別研究事業, 平成21年度研究報告書. 2010. p.73-74.
 
7) 伊藤博明. 事前指示と事前ケア計画-「想定外」に対応する方法の考察-. 国立医療学会誌 2014 ; 68 (4) : 170-174.
 
8) 川島孝一郎. 神経難病在宅ケアの実践と心構え 問題解決への道. 総合診療 2015 ; 25 (3) : 246-249.
 
P.261 掲載の参考文献
1) 厚生労働省ホームページ
 
2) 日本緩和医療学会ホームページ
 
3) 日本ホスピス緩和ケア協会ホームページ
 
P.268 掲載の参考文献
1) 事前指示書 : 国立研究開発法人 国立長寿医療研究センター 在宅連携医療部. http://www.ncgg.go.jp/zaitaku1/eol/ad/2kaisetsu.html
 
2) Jonsen AR, Siegler M, Winslade WJ : Clinical Ethics-A Practical Approach to Ethical Decisions in Clinical Medicine (3rd ed.). McGraw-Hill, New York, 1992. ; 日本語翻訳版 : 赤林 朗, 大井玄監訳. 臨床倫理学 : 臨床医学における倫理的決定のための実践的なアプローチ. 新興医学出版社, 1997.
 
P.278 掲載の参考文献
1) 宇野正威. 「もの忘れ」の処方箋. 日本放送出版協会 ; 2003.
 

書評

最近チェックした商品履歴

Loading...